Abstract
The aim of this report is to describe the feasibility and tolerability of medical treatment with sacubitril/valsartan in a patient treated with hemodialysis. We describe the case of a 67-year-old man with heart failure with reduced ejection fraction due to an ischemic cardiomyopathy and renal insufficiency undergoing hemodialysis. Because of worsening heart failure with no other therapeutic options, a treatment with sacubitril/valsartan was started. Although this patient had a very low systolic blood pressure, he could tolerate a moderate dose of 49/51 mg twice daily. After initiation of sacubitril/valsartan, there was a symptomatic improvement with a clear reduction NT-proBNP, accompanied by a decrease in filling pressures. In conclusion, in this patient with severe heart failure undergoing hemodialysis, treatment with sacubitril/valsartan was feasible, safe, and improved heart failure symptoms.
Author supplied keywords
Cite
CITATION STYLE
Heyse, A., Manhaeghe, L., Mahieu, E., Vanfraechem, C., & Van Durme, F. (2019). Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Failure, 6(6), 1331–1333. https://doi.org/10.1002/ehf2.12544
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.